RESEARCH ARTICLE The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Objectives The mammalian target of rapamycin (mTOR) and phosphorylated mTOR (p-mTOR) are po-tential prognostic markers and therapeutic targets for non-small cell lung cancer (NSCLC). However, the association between mTOR/p-mTOR expression and NSCLC patients ’ prog-nosis remains controversial. Thus, a meta-analysis of existing studies evaluating the prog-nostic role of mTOR/p-mTOR expression for NSCLC was conducted. Materials and Methods A systemically literature search was performed via Pubmed, Embase, Medline as well as CNKI (China National Knowledge Infrastructure). Studies were included that reported the hazard ratio (HR) and 95%CI for the association between mTOR/p-mTOR expression and NSCLC patients ’ survival. Random-effects model was used to pool HRs. Results Ten eligible studies were included in this meta-analysis, with 4 about m-TOR and 7 about p-mTOR. For mTOR, the pooled HR of overall survival (OS) was 1.00 (95%CI 0.5 to 1.99) by univariate analysis and 1.22 (95%CI 0.53 to 2.82) by multivariate analysis. For p-mTOR, the pooled HR was 1.39 (95%CI 0.97 to 1.98) by univariate analysis and 1.42 (95%CI 0.56 to 3.60) by multivariate analysis. Conclusion The results indicated that no statistically significant association was found between mTOR/ p-mTOR expression and NSCLC patients ’ prognosis